Pharmacogenomics and the resulting impact on psoriasis therapies

Research output: Contribution to journalArticlepeer-review


Psoriasis is a model disease for the development of pharmacogenomic markers of treatment response, with ready access to diseased tissue and objective validated outcome measures. With the application of state-of-the-art technologies and investment in careful experimental design, the goal of stratified medicine in psoriasis may be possible. Current pharmacogenomic studies in psoriasis show excellence in many areas, including the investigation of a broad range of psoriasis therapies. To facilitate the advent of stratified medicine in psoriasis, uniformity of study design is required, with high quality, consistent phenotyping strategies for participants; definitions of outcome; and the publication of reproducible methodologies.

Original languageEnglish
Pages (from-to)149-60
Number of pages12
JournalDermatologic clinics
Issue number1
Publication statusPublished - Jan 2015


  • Acitretin
  • Cyclosporine
  • Cytokines
  • HLA-C Antigens
  • Humans
  • Immunosuppressive Agents
  • Inflammation
  • Keratolytic Agents
  • Methotrexate
  • Pharmacogenetics
  • Phototherapy
  • Polymorphism, Genetic
  • Precision Medicine
  • Psoriasis
  • Research Design
  • Tumor Necrosis Factor-alpha


Dive into the research topics of 'Pharmacogenomics and the resulting impact on psoriasis therapies'. Together they form a unique fingerprint.

Cite this